Showing 1 - 10 of 29
Persistent link: https://www.econbiz.de/10011317762
Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. Aim: To compare the economic impact of two icatibant administration strategies: health...
Persistent link: https://www.econbiz.de/10009755347
Background: Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on the impact of routine vaccination is stated as one of the reasons. As a...
Persistent link: https://www.econbiz.de/10010242226
Background: As a direct result of the population growing older the total number of chronic illnesses increases. The future expenditure for care of chronically ill patients is an ever-present challenge for the health care system. New solutions based on integrated care or the inclusion of...
Persistent link: https://www.econbiz.de/10010242232
Persistent link: https://www.econbiz.de/10011486230
Persistent link: https://www.econbiz.de/10011541404
Persistent link: https://www.econbiz.de/10012221328
Persistent link: https://www.econbiz.de/10012221637
Persistent link: https://www.econbiz.de/10012421458
Cost-utility analyses undertaken to inform decision making regarding colorectal cancer (CRC) require a set of health state utility values (HSUVs) so that the time CRC patients spend in different health states can be aggregated into quality-adjusted life-years (QALY). This study reviews...
Persistent link: https://www.econbiz.de/10011586610